Metronidazole in periodontitis. I. Clinical and bacteriological results after 15 to 30 weeks.
The statistical association of certain anaerobic organisms such as black pigmented bacteroides (BPB) species and spirochetes with clinical signs of active periodontitis, i.e. bleeding upon probing and bone loss, suggests that the lesions may actually reflect a "specific infection" involving these or unidentified species. All the known oral species of BPB and spirochetes are anaerobes which suggests that antimicrobial treatment directed specifically against anaerobes might be effective in periodontal therapy. In this report, the short-term results of metronidazole treatment plus mechanical debridement in patients with extensive periodontal disease and of a double-blind clinical study in which metronidazole plus mechanical debridement is compared to placebo plus mechanical debridement are described. The findings indicate that 1 week of systemic metronidazole can optimize the clinical reduction of pockets and increase the apparent attachment in periodontitis patients who receive concurrent mechanical debridement of their root surfaces. In patients with extensive clinical involvement, metronidazole resulted in a significant reduction in the number of sites exhibiting pocket depths and attachment loss greater than or equal to 7 mm. When metronidazole plus mechanical debridement was compared with placebo plus mechanical debridement in a double-blind study, the metronidazole patients exhibited a significant improvement in those sites initially greater than or equal to 7 mm. The beneficial effect of the metronidazole was associated with a significant and sustained reduction of certain anaerobic organisms such as Bacteroides gingivalis and the large spirochetes. These data indicate that treatment aimed specifically toward the anaerobic component of the plaque flora can be associated with impressive clinical improvements 15 to 30 weeks after the initiation of treatment.
D000539:Alveolar Process / Q000382:microbiology; D001421:Bacteria, Anaerobic / Q000187:drug effects / Q000302:isolation & purification; D001439:Bacteroides / Q000187:drug effects / Q000302:isolation & purification; D001862:Bone Resorption / Q000188:drug therapy / Q000382:microbiology; D003777:Dental Prophylaxis; D012534:Dental Scaling; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use*; D010518:Periodontitis / Q000188:drug therapy* / Q000382:microbiology / Q000628:therapy; D010919:Placebos; D013144:Spirochaetales / Q000187:drug effects / Q000302:isolation & purification
D010919:Placebos; D008795:Metronidazole